Key takeaways:

A monthly injection of olezarsen reduced triglyceride levels in adults with elevated cardiovascular risk.

More than 80% of patients assigned olezarsen achieved a normal triglyceride level at 6 months.

Monthly olezarsen reduced triglyceride levels by up to 60% at 6 months among patients with moderate hypertriglyceridemia and elevated cardiovascular risk.

Treatment with olezarsen (Tryngolza, Ionis Pharmaceuticals) also lowered levels of remnant cholesterol, non-HDL cholesterol and apolipoprotein B, with no change in LDL cholesterol, according to results from the phase 3 Essence-TIMI 73b trial.

A monthly injection of olezarsen reduced triglyceride levels in adults with elevated cardiovascular risk. Image: Adobe Stock

“This triglyceride effect was greater than is possible

See Full Page